Myelofibrosis with myeloid metaplasia

New England Journal of Medicine

Volumn 342, Issue 17, 2000, Pages 1255-1265

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; ANDROGEN; ANGIOGENESIS INHIBITOR; ANTIFIBROTIC AGENT; CORTICOSTEROID; HYDROXYUREA; RECOMBINANT ALPHA INTERFERON; SURAMIN; THALIDOMIDE;

CLINICAL FEATURE; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; MYELOFIBROSIS; MYELOID METAPLASIA; NUCLEAR MAGNETIC RESONANCE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; BONE MARROW; DIAGNOSIS, DIFFERENTIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYUREA; MYELOFIBROSIS; MYELOID METAPLASIA; PROGNOSIS; SPLENECTOMY; SURAMIN;

EID: 0034720161     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200004273421706     Document Type: Review

References (89)

1. Neuwirtova R, Mocikova K, Musilova J, et al. Mixed myelodysplastic and myeloproliferative syndromes. Leuk Res 1996;20:717-26.
2. Ward HP, Block MH. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore) 1971;50:357-420.
3. Moran CA, Suster S, Fishback N, Koss MN. Extramcdullary hematopoiesis presenting as posterior mediastinal mass: a study of four cases. Mod Pathol 1995;8:249-51.
4. McCarthy DM. Fibrosis of the bone marrow: content and causes. Br J Haematol 1985;59:1-7.
5. O'Keane JC, Wolf BC, Neiman RS. The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma. Cancer 1989;63:1539-43.
6. Vandermolen L, Rice L, Lynch EC. Plasma cell dyscrasia with marrow fibrosis: clinicopathologic syndrome. Am J Med 1985;79:297-302.
7. Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer 1997;80:708-19.
8. Najean Y, Arrago JP, Rain JD, Dresch C. The 'spent' phase of polycythaemia vera: hypersplenism in the absence of myclofibrosis. Br J Haematol 1984;56:163-70.
9. Ellis JT, Peterson P, Geller SA, Rappaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol 1986;23:144-55.
10. Tsukamoto N, Morita K, Maehara T, et al. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement. Br J Haematol 1994;86: 253-8.
11. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myclofibrosis. Blood 1978;51:189-94.
12. Ruutu T, Partanen S, Knuutila S. Clonal karyotype abnormalities in erythroid and granulocyte-monocyte precursors in polycythaemia vera and myelofibrosis. Scand J Haematol 1983;31:253-6.
13. Buschle M, Janssen JW, Drexler H, Lyons J, Anger B, Bartram CR. Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia 1988; 2:658-60.
14. Wang JC, Lang HD, Lichter S, Weinstein M, Benn P. Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia. Br J Haematol 1992;80:184-8.
15. Castro-Malaspina H, Gay RE, Jhanwar SC, et al. Characteristics of bone marrow fibroblast colony-forming cells (CFU-F) and their progeny in patients with myeloproliferative disorders. Blood 1982;59:1046-54.
16. Thiele J, Braeckel C, Wagner S, et al. Macrophages in normal human bone marrow and in chronic myeloproliferative disorders: an immunohistochemical and morphometric study by a new monoclonal antibody (PG-MI) on trephine biopsies. Virchows Arch 1992;421:33-9.
17. Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev 1997;11:233-42.
18. Mesa RA, Rajkumar SV, Hanson CA, Schroeder GS, Tefferi A. Evaluation and clinical correlations of microvessel density in myelofibrosis with myeloid metaplasia. Blood 1999;94:Suppl 1:115a. abstract.
19. Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 1997;97:441-8.
20. Katoh O, Kimura A, Itoh T, Kuramoto A. Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders. Am J Hematol 1990;35:145-50.
21. Long MW, Robinson JA, Ashcraft EA, Mann KG. Regulation of human bone marrow-derived osteoprogenitor cells by osteogenic growth factors. J Clin Invest 1995;95:881-7. [Erratum, J Clin Invest 1995;96:2541.]
22. Castro-Malaspina H, Rabellino EM, Yen A, Nachman RL, Moore MA. Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood 1981;57:781-7.
23. Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994;88:9-16.
24. Terui T, Niitsu Y, Mahara K, et al. The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood 1990;75:1540-8.
25. Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1997;90:4369-83.
26. Yanagida M, Ide Y, Imai A, et al. The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol 1997;99:739-45.
27. Rameshwar P, Denny TN, Stein D, Gascon P. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines: potential role for interleukin-1 and TGF-beta. J Immunol 1994;153:2819-30.
28. Kimura A, Katoh O, Hyodo H, Kuramoto A. Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts. Br J Haematol 1989;72:486-91.
29. Dalley A, Smith JM, Reilly JT, Neil SM. Investigation of calmodulin and basic fibroblast factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation. Br J Haematol 1996;93:856-62.
30. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 1997;94:663-8.
31. DiBella NJ, Silverstein MN, Hoagland HC. Effect of splenectomy on teardop-shaped erythrocytes in agnogenic myeloid metaplasia. Arch Intern Med 1977;137:380-1.
32. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single institutional experience with 223 patients. Blood (in press).
33. Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders: incidence among subtypes according to the Hannover Classification. Pathol Res Pract 1993;189:121-32.
34. Verhoef GE, De Wolf-Peeters C, Ferrant A, et al. Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. Ann Hematol 1991;63:235-41.
35. Rubins JM. The role of myelofibrosis in malignant leukoerythroblastosis. Cancer 1983;51:308-11.
36. Meadows LM, Rosse WR, Moore JO, Crawford J, Laszlo J, Kaufman RE. Hodgkin's disease presenting as myelofibrosis. Cancer 1989;64:1720-6.
37. Reilly JT, Snowden JA, Spearing RL, et al. Cytogcnetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 1997;98:96-102.
38. Truong LD, Saleem A, Schwartz MR. Acute myelofibrosis: a report of four cases and review of the literature. Medicine (Baltimore) 1984;63:182-7.
39. Vallespi T, Imbert M, Mecucci C, Preudhomme C, Fenaux P. Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica 1998;83:258-75.
40. Miller JB, Testa JR, Lindgren V, Rowley JD. The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis. Cancer 1985;55:582-91.
41. Thiele J, Zankovich R, Steinberg T, Kremer B, Fischer R, Diehl V. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis - a critical evaluation of clinical and histomorphological data. Acta Haematol 1989;81:192-202.
42. Tefferi A. Risk-based management in essential thrombocythemia. In: Schechter GP, Hoffman R, Schrier SL, eds. Hematology 1999: American Society of Hematology education program book. Washington, D.C.: American Society of Hematology, 1999:172-7.
43. Maschek H, Georgii A, Kaloutsi V, et al. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol 1992;48:208-14.
44. Smith JW, Shulman HM, Thomas ED, Fefer A, Buckner CD. Bone marrow transplantation for acute myelosclerosis. Cancer 1981;48:2198-203.
45. Cripe LD, Hromas R. Malignant disorders of megakaryocytes. Semin Hematol 1998;35:200-9.
46. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the UK. Hematol Oncol 1997; 15:173-89.
47. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study, 1976-1995. Am J Hematol 1999;61:10-5.
48. Chaiter Y, Brenner B, Aghai E, Tatarsky I. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymphoma 1992;7:251-5.
49. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996;88:1013-8.
50. Cervantes F, Pereira A, Esteve J, et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997;97:635-40.
51. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998;102:684-90.
52. Sekhar M, Prentice HG, Popat U, et al. Idiopathic myelofibrosis in children. Br J Haematol 1996,93:394-7.
53. Altura RA, Head DR, Wang WC. Prolonged survival of children with idiopathic myelofibrosis (IMF). Blood 1999;94:Suppl 1:114a. abstract.
54. Wolf BC, Banks PM, Mann RB, Neiman RS. Splenic hematopoiesis in polycythemia vera: a morphologic and immunohistologic study. Am J Clin Pathol 1988;89:69-75.
55. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990;75:4-9.
56. Thiele J, Windecker R, Kvansnicka HM, Titius BR, Zankovich R, Fischer R. Erythropoiesis in primary (idiopathic) osteomyelofibrosis: quantification, PCNA-reactivity, and prognostic impact. Am J Hematol 1994; 46:36-42.
57. Silverstein MN, Wollaeger EE, Baggenstoss AH. Gastrointestinal and abdominal manifestations of agnogenic myeloid metaplasia. Arch Intern Med 1973;131:532-7.
58. Wanless IR, Peterson P, Das A, Boitnott JK, Moore GW, Bernier V. Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy. Hepatology 1990;12:1166-74.
59. Tefferi A, Barrett SM, Silverstein MN, Nagorney DM. Outcome of portal-systemic shunt surgery for portal hypertension associated with intrahepatic obstruction in patients with agnogenic myeloid metaplasia. Am J Hematol 1994;46:325-8.
60. Jaroch MT, Broughan TA, Hermann RE. The natural history of splenic infarction. Surgery 1986;100:743-50.
61. Bartlett RP, Greipp PR, Tefferi A, Cupps RE, Mullan BP, Trastek VF. Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion. Mayo Clin Proc 1995;70:1161-4.
62. Mason BA, Kressel BR, Cashdollar MR, Bernath AM, Schechter GP. Periostitis associated with myelofibrosis. Cancer 1979;43:1568-71.
63. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991;67:2658-63.
64. Rupoli S, Da Lio L, Sisti S, et al. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol 1994;68:205-12.
65. Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E. The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. Eur J Haematol 1998;60:101-5.
66. Varki A, Lottenberg R, Griffith R, Reinhard E. The syndrome of idiopathic myelofibrosis: a clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine (Baltimore) 1983;62:353-71.
67. Demory JL, Dupriez B, Fenaux P, et al. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood 1988;72:855-9.
68. Silverstein MN. Agnogenic myeloid metaplasia. Acton, Mass.: Publishing Sciences Group, 1975.
69. Hasselbalch HC. Idiopathic myelofibrosis - an update with particular reference to clinical aspects and prognosis. Int J Clin Lab Res 1993;23: 124-38.
70. Besa EC, Nowell PC, Geller NL, Gardner FH. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer 1982; 49:308-13.
71. Levy V, Bourgarit A, Delmer A, et al. Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases. Am J Hematol 1996;53: 239-41.
72. Gilbert HS. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer 1998;83:1205-13.
73. Tefferi A, Silverstein MN, Li CY. 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 1997;99:352-7
74. Rodriguez JN, Martino ML, Dieguez JC, Prados D. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia: experience in 6 patients and meta-analytical approach. Haematologica 1998;83:616-21.
75. Mesa RA, Li C-Y, Schroeder GS, Tefferi A. Clinical correlates of splenic histopathology in myelofibrosis with myeloid metaplasia. Blood 1999; 94:Suppl 1:115a. abstract.
76. Barosi G, Ambrosetti A, Centra AL, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Blood 1998; 91:3630-6.
77. Elliot MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 1998;103:505-11.
78. Koeffler HP, Cline MJ, Golde DW. Splenic irradiation in myelofibrosis: effect on circulating myeloid progenitor cells. Br J Haematol 1979;43:69-77.
79. Rajantie J, Sale GE, Deeg HJ, et al. Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood 1986;67:1693-7.
80. Soll E, Massumoto C, Clift RA, et al. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 1995;86:4667-73.
81. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood 1999;93:2381-8.
82. Guardiola P, Esperou H, Cazals-Hatem D, et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Br J Haematol 1997;98:1004-9.
83. Anderson JE, Deeg HJ, Tefferi A, et al. Effective treatment of myelofibrosis (MF) by autologous peripheral blood stem cell (PBSC) transplantation (PBSCT). Blood 1999;94:Suppl 1:396a. abstract.
84. Solberg LA Jr, Tefferi A, Oles KJ, et al. The effects of anagrelide on human megakaryocytopoiesis. Br J Haematol 1997;99:174-80.
85. Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1999;106:682-8.
86. Tefferi A, Silverstein MN, Plumhoff EA, Reid JM, Ames MM. Suramin toxicity and efficacy in agnogenic myeloid metaplasia. J Natl Cancer Inst 1993;85:1520-2.
87. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999;159:1061-9.
88. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-5.
89. Thomas DA, Aguayo A, Giles FJ, et al. Thalidomide anti-angiogenesis therapy (Rx) in Philadelphia (Ph)-negative mycloproliferative disorders (MPD) and myelofibrosis (MF). Blood 1999;94:Suppl 1:702a. abstract.